bioengineering

News

CAR-T therapies have revolutionised the treatment of some blood cancers, but are costly as well as time- and resource-intensive.

News

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.